IBA and partners launch significant clinical trial to improve patient selection for proton therapy
IBA (Ion Beam Applications S.A.) announces the launch of a large-scale, multi-institutional, randomized controlled clinical trial in conjunction with 19 industry and academic partners. The consortium will conduct the “ProtectTrial” in esophageal cancer with the aim of improving access to proton therapy for patients, whilst validating a model-based approach for the use of proton therapy treatment in cancer more broadly.
IBA and UMCG, along with 5 other IBA equipped proton therapy centers in the EU, are taking part to this research project. The research project comprises 12 proton therapy centers across eight countries and is coordinated by Professor Cai Grau from Aarhus University in Denmark. A total of approximately 400 patients are expected to be included in the randomized trial with study completion planned by 2027.
The broader aim of the collaboration is to improve patient selection for proton therapy across cancer indications through the evaluation of selection criteria and the creation of shared reimbursement guidelines. A new consensus model would be of clear value across Europe, for both patient referral and treatment. The “ProtectTrial” project is clearly in line with the work carried out in the Work Package 8 of the Inspire project which is aimed at looking at parameters for selection of patients for proton therapy treatment. Although proton therapy treatment is growing across Europe it is still a relatively rare resource. Consequently, methods need to be developed that the patient who will benefit most from this treatment can be identified. The Inspire WP8 and the ProtecTrial are clearly working to that aim.
To read more on this article please click here or visit https://protecttrial.eu/.